In the June 2007
issue:
Mylan Wins Merck’s Generics Unit
Pays $6.7 Billion For Global Expansion
After a months-long bidding process, Mylan
Laboratories is
paying $6.7 billion to acquire Merck’s generics business.
Completion of the deal will make Mylan the world’s fourth-largest generics
company.
The bidding process reveals as much about the losing bidders’ strategic
goals as it does about Mylan’s.
...
May’s M&A Activity Strong
72 Deals Announced Worth $28.4 Billion
May saw a total of 72 mergers and acquisitions in the health care industry,
worth a total of $28.4 billion.
Year to date, the M&A market has produced 365 deals worth a combined total
of $125.0 billion in a scorching, record-setting pace.
...
In the Departments
Services
-Health Care Services
-Deal Summaries
-Additional Transactions
-Transaction Updates
Technology
-Deal Summaries
-Additional Transactions
-Transaction Updates -Health Care Technology
Sign up for a trial subscription and get
the current issue!
Read more about
The Health Care M&A Monthly.
Articles Archive
Companies Mentioned in this issue:
June 2007
5AM Ventures p 11
A
ABS Ventures p 10
ABV Holding Co. p 11
Acura Pharmaceuticals p 14
Advanced BioHealing p 11
Advanced Cell Tech.
p 8
Advanced Magnetics
p 4
Advanced Technology Ventures p 10
Advanced Technology Ventures p 10, p 11
Advancis Pharmaceut. p 4
Aegerion Pharmaceut. p 4
Aeolus Pharmaceuticals p 14
Aescap Venture Management p 11
Aetna p 8
Aetna Ventures p 11
Albany Molecular Res. p 8
Alliance Hospital p 8
Alliance Imaging p 4
AllianceBernstein p 9
Alta Partners p 10,
p 11
Alternative Treatment International p 16
Altitude Life Science Ventures p 10
Ambrilia Biopharma
p 14
Amedica p 4, p 11
American Society of Plastic Surgeons p 16
Amicus Therapeutics p 4
AMN Healthcare Svs. p 8
AmSurg Corporation
p 8
Andover Medical p 14
Annual Scientific Assembly of the American Thoraci
p 15
Antares Pharma p 14
Aperio Technologies
p 11
APNEX Medical p 11
Arcturus Capital p 11
Array Biopharma p 4
Ascension Health Ventures p 11
Asmacure p 11
Asthmatx p 15
ATC Healthcare Svs.
p 8
Atlantis Components p 11
AtriCure p 14
Avalon Pharmaceuticals p 13
AVEO Pharmaceuticals p 15
Avestha Gengraine Technologies p 11
Avid Radiopharmaceuticals p 11
Axxora Life Sciences p 8
B
BaroFold p 11
Barr Pharmaceuticals p 7
Bauch & Lomb p 8
Bausch & Lomb p 9
BBT Fund p 10, p 15
Be-Tabs Pharmaceuticals p 8
Bear, Stearns p 4
Beecken Petty O’Keefe & Company
p 7
Berry Medical Employment p 8
Bessemer Venture Partners p 10, p 11
Bio-Imaging Research p 8
Bio-Rad Laboratories p 8
Bioabsorbable Therapeutics p 11
Bioenvision p 8
Biogen Idec p 15
Biolex Therapeutics
p 10
BioMedical Ventures
p 10
Biomerk p 8
BioProgress p 8
Biosante Pharmaceuticals p 14
Biosite p 8, p 9
BioStorage Technologies p 11
Biotechnology Value Fund p 13
Blackmont Capital
p 13
Boston Life Sciences p 14
Boulder Ventures
p 11
Bovie Medical p 8
Bristol-Myers Squibb p 8
Brooks Eckerd Pharmacy p 7
Brookside Capital p 9
Burrill & Company
p 11
C
Cambridge Heart p 4
Cantor Fitzgerald p 4
Canyon Creek Devel. p 8
Cardinal Health p 7,
p 8
CardioMEMS p 4
CardioVascular BioTherap. p 14
Cardiovascular Innovations p 8
Cardium Therapeutics p 4
Catella Healthcare
p 10
CCS Medical Holdings p 4
Ception Therapeutics p 11
Champions Biotechnol. p 8
Charles Street Securities p 11
Chattem p 8
CIBC p 4
CIDC p 10
Citi p 4
Clayton, Dublier & Rice p 9
Community Hlth. Sys. p 8
Connecticut Innovations p 11
Cowen p 4
Creation Capital p 11
Credit Suisse p 4
Crest p 16
Cumberland Pharma. p 4
Cypress Bioscience
p 4
Cytyc p 7, p 8
D
D.A. Davidson p 4
Delphi Ventures p 10
Deutsche Bank p 4
Devonshire PGA National p 8
DFJ Frontier p 11
DiaMed Holding p 8
Digirad p 8
Domain Associates
p 11
Dow Venture Capital
p 10
E
Earlybird Venture Capital p 11
Easton Capital p 10
Encorium Group p 14
Endocare p 14
EndoCeutics p 4
Ensign Group p 4
EnteroMedics p 4
Enzo Biochem p 8
Essex Woodlands
p 11
ETF Venture Funds
p 7
Eurand N.V. p 4
EvoGenix p 8
F
Federated Kaufmann Fund p 13
Finistere Ventures
p 11
FirmInvest AG p 14
First Albany Capital
p 4
Flagship Ventures
p 10
Fonds Bio-Innovation p 11
Forest Laboratories
p 16
Foundation Capital
p 11
Foundation Medical Partners p 10
Frazier Healthcare
p 10, p 11
Frazier Healthcare Partners p 15
Frazier Healthcare Technology p 10
Frazier Healthcare Ventures p 10
Frazier Healthcare Ventures p 14
Fusion Capital. p 4
G
Galen Partners p 11
Genomic Health p 4
Genzyme Corporation p 8
Goldman, Sachs p 9
GPC Biotech p 12
Green Light Capital
p 11
H
H&B Capital p 10
Halozyme Therapeutics p 12
HBM BioVentures (Cayman) p 11
HealthSport p 8
Helicos Biosciences
p 4
Hemispherx Biopharma p 4
Hercules Healthcare Technology Growth Capital p 10
Highland Capital p 10
Highland Capital Management p 14
Hologic p 7, p 8
Hunt BioVentures
p 13
I
Iasis Healthcare p 8
IBG p 10
IBTM p 10
ImaRx p 4
Immunomedics p 13
InfoLogix p 8
Innovatech Quebec
p 11
Innoven Partenaires p 14
InnoZen p 8
Inovio Biomedical
p 14
Insmed p 14
Insulet p 4
InteliStaf Holdings
p 8
Intersouth Partners
p 10
Interventional Spine p 11
InterWest Partners
p 10
InterWest Partners
p 10, p 11
Intrexon p 11
Inverness Medical
p 8, p 9
Investor Growth Capital p 10, p 11
IOMED p 8
ITX International Equity p 11
J
J-Plasma p 8
Javelin Pharmaceutic. p 4
Jazz Pharmaceuticals p 4
Jefferies & Co. p 4
JM Financial p 15
John Curtin School of Medical Research at The Aust p 12
Johnson & Johnson Development Corporation p 10
Johnson & Johnson Development Corporation p 15
Johnson Matthey PLC p 14
JPMorgan p 4
K
Kleiner Perkins Caufield & Byers p 11
L
Latterell Venture Partners p 11
Lazard Capital Markets p 12, p 13
Lehman p 4
LehmanBrown International Accountants p 9
LeMaitre Vascular p 8
Life Without Pain p 8
Lusora Healthcare Systems p 14
Lux Capital p 11
M
Madison Dearborn
p 8, p 9
Manhattan Pharmaceu. p 4
Marcadia Biotech p 11
Maxim Group p 4
Maxor Natl. Pharmacy p 8
McGraw-Hill Construction p 16
Medcath p 4
Medical Staffing Ntwk. p 8
MemberHealth p 8
Merck KGaA p 7, p 8
Merlin BioMed Group p 10
Merlin Nexus p 13
Merrill Lynch p 4
Mitsubishi UFJ Financial Group p 10
Mitsui & Co. Venture Partners p 10
Modigene p 14
MonoSol Rx p 4
Morgan Stanley p 4,
p 11
Morria Biopharmaceuticals
p 11
MPM BioVentures IV
p 11
MPM Capital p 11
Mylan Laboratories
p 7, p 8
Mytogen p 8
N
Nationwide Health p 4
Naviscan PET Systems p 11
NeuroVista p 10
New Enterprise Associates p 11
New River Management V p 11
New River Management V, LP
p 12
New York Life Investment Management India Fund p 11
NitroMed p 4
Novadaq Technologies p 13
Novartis p 7
Novartis Venture Fund p 11
NOXXON Pharmaceuticals p 10
O
Olympus Medical Systems p 15
Omnicell p 4
ONSET Ventures p 11
Oppenheimer & Co.
p 12
Oppenheimer & Company p 4
Orange Medical p 9
Osco Drug p 7
Oxford Bioscience Partners p 10
P
Pacific Growth Eq. p 4
PainCare Holdings
p 4
PAION AG p 16
Pantarhei Bioscience p 14
Passport Management p 13
Pegasus Biologies
p 11
Peptech Limited p 8
Perceptive Life Sciences Master Fund p 14
Pharmion p 4
Pharmion Corporation p 14
Pharmion GmbH p 14
Piper Jaffray p 4,
p 14
PLC Medical System
p 13
Polaris Venture Partners p 10, p 11
Porter Health p 8
Portola Pharmaceuticals p 9
Power Medical Interven. p 4
Premise p 11
ProCertus Biopharm
p 11
Progen Pharmaceuticals p 12, p 13
Prolacta Biosciences
p 11
ProMed Healthcare
p 8
Prospect Ventures
p 10
Prospect Medical p 8
Prospect Venture Partners p 10
ProtAffin Biotechnologie p 11
Q
Quaker BioVentures
p 10
Quantum Group p 14
Quantum Technology p 11
QuatRx p 10
QuatRx Pharmaceuticals p 15
Quest Group p 8
QuestMark Partners
p 11
R
Radiation therapy center p 8
Radiation Thrpy. Svs. p 8
Radius Ventures p 11
Ranbaxy Laboratories p 8
RBC Dominion Securities p 13
ReAble Therapeutics p 8
Reliance Life Sciences p 11
Research and Markets p 9
Rigel Pharmaceuticals p 4
Rite Aid Corporation
p 7
River Rock Lodge p 8
Rodman & Renshaw
p 12, p 14
Rothschild Investment Partners p 10
Royalty Pharma p 8
Rx Pro Health p 8
S
Safeguard Scientifics p 11
Sanderling Ventures
p 11
Sandoz p 7
Sav-on Drugs p 7
Savannah Commons p 8
Savvian Advisors p 14
Schaller Anderson p 8
Schering-Plough p 8, p 15
Secure Pharmacy Plus p 8
Selah SeniorCare p 8
Sidec Technologies
p 11
SightLine Partners
p 10
Signet Healthcare Partners p 11
Skilled Healthcare Group p 4
Sofinnova Partners
p 10
Solace Pharmaceuticals p 11
Special Situations Life Sciences Fund p 13
SpectraScience p 14
Spectrum Pharmaceuticals p 12
Spring Mills Venture Partners p 11
Sprout Group p 10
Standard Mgmt. Corp. p 8
STARLIMS Technol.
p 4
Stifel Nicolaus p 4
Stockwell Capital p 10
StrataGent Life Sciences p 11
Sun Pharmaceutical
p 8
Sunesis Pharmaceutic. p 4
Sutter Hill Ventures
p 10
T
T. Rowe Price p 9
Take Care Health Systems p 7
Talima Therapeutics p 11
Targanta Therapeutics p 4
Taro Pharmaceutical p 8
Teachers’ Private Capital p 10
Tempo Pharmaceuticals p 11, p 15
Teva Pharmaceuticals p 7
Therative p 11
ThinkEquity Partners p 12
Third Point p 11
Thomas Weisel p 4
Thomas Weisel Healthcare Partners
p 10
Thomas Weisel Partners p 4, p 12,
p 15
Three Arch Partners
p 10, p 11
TL Ventures p 10
TomoTherapy p 4
TorreyPines Therapeu. p 4
Turenne Capital p 14
Turner Construction Company p 16
TVM Capital p 10
U
UBS p 4
UCB, S.A. p 13
Ultrascan p 8
Universal American
p 8
University of Pittsburgh School of Medicine p 16
US Venture Partners
p 11
V
Valera Holdings p 10
Varian p 8
Vectura Group p 16
Venrock p 11, p 15
Venrock Partners p 10
Ventas p 4
Venture Investors
p 11
Versant Partners p 13
VIASYS Healthcare
p 8, p 9
Viragen p 4
VirtualScopics p 4
Vivo Ventures p 9
Vivo Ventures VI p 9
VWR International
p 8, p 9
W
Walgreen Co. p 7
Warburg Pincus p 8,
p 9
Wexford Capital p 11
X
Xillix Technologies
p 13
Y
Younger America p 8
Z
Z-Cube p 11 |
May’s M&A Activity Strong
72 Deals Announced Worth $28.4 Billion
Email Editor
The month of May saw the announcement of 72 mergers and
acquisitions in the 13 sectors of the health care industry. The four
sectors of the health care technology segment accounted for 38 of those
transactions, or 53% of the total, while the nine sectors of the health
care services segment produced the remaining 34 deals.
In terms of deal volume, the Biotechnology, Medical Device
and Pharmaceutical sectors tied for first place with each sector
announcing 12 transactions. These three combined represent half of the
month’s deal volume.
In the services segment, Hospitals reported the highest
deal volume, with six transactions, and was followed by Long-Term Care
with five and Managed Care with four. By contrast, post-acute care service
sectors languished, with Home Health Care producing just one deal and
Rehabilitation none.
Based on prices revealed to date, a total of $28.4 billion
was committed to fund this robust M&A activity. By itself, the technology
segment accounted for $23.5 billion, or 83% of the month’s total dollar
volume. Deals in the services segment, by contrast, accounted for the
remaining $4.9 billion. May produced a total of six billion-dollar deals,
with three in Medical Devices and one each in Biotechnology,
Pharmaceuticals and Laboratory Services (in "Other"). Their combined value
is approximately $23.8 billion.
Seven of this month’s transactions were carried out by
financial buyers, including private equity firms. Although they account
for just 10% of the deal volume, they represent $8.3 billion, or nearly
30% of the dollar volume.
The first five months of 2007 have produced a total of 365
mergers and acquisitions in the health care industry worth a combined
total of $125.0 billion. If the market can sustain this galloping pace,
2007 will end up in the history books with nearly 900 deals worth a
record-shattering $300.0 billion.
|
|
FREE TRIAL
TO THE
HEALTH CARE M&A INFORMATION SERVICE!
If you like this article, there’s lots more
waiting for you in The Healthcare M&A Information Service. It’s the
bible of what's going on in health care M&A today.
Sign up for two free months right now! There’s no
obligation, no writing “cancel” on a bill. Happy reading!
|
|
